جميع الدراسات
نشط غير مجندالمرحلة 4تدخلي

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

This research study is for people aged 12 and older who have hereditary angioedema, a rare condition causing swelling attacks. The main goal is to check the safety of a new treatment called garadacimab. Participants will switch to garadacimab from their current regular preventative medicine for HAE. This could be a kallikrein inhibitor or a medicine derived from human plasma. The study will look at how people respond when they take garadacimab once a month for about three months. It's a 'Phase 4' study, meaning the medicine is already approved for some uses, and researchers are gathering more information on its safety when used in a new way or by a new group of people. This helps doctors understand if it's a good alternative for patients.

نظرة سريعة

الحالة
نشط غير مجند
المرحلة
المرحلة 4
الراعي
CSL Behring
الهدف من التسجيل
18
ابدأ
٢٨ أبريل ٢٠٢٥
التاريخ المتوقع للانتهاء
٢٣ يونيو ٢٠٢٦

ما هو موضوع هذه الدراسة؟

This study is about a medicine called garadacimab and its safety for people who have hereditary angioedema (HAE). HAE is a condition that causes sudden, painful swelling in different parts of the body, like the face, hands, feet, or tummy. This swelling can be quite severe and sometimes life-threatening. Many people with HAE take regular medicines to try and prevent these attacks from happening; these are called 'preventative' or 'prophylactic' treatments.

In this study, researchers want to see what happens when people who are already taking one of these regular preventative HAE medicines switch to garadacimab. They are particularly interested in how safe this switch is and how well people tolerate the new medicine. Garadacimab will be given once a month for around three months to see its effects.

This kind of study, called a 'Phase 4' study, usually happens after a medicine has already been approved and is available. It helps doctors and researchers learn more about the medicine in real-world settings, especially when patients change from one treatment to another. Understanding the safety of switching treatments is important for doctors to help their patients manage HAE effectively.

النقاط الرئيسية

  • This study is for people aged 12 and over with hereditary angioedema (HAE).
  • It researches the safety of switching to a medicine called garadacimab.
  • Participants will take garadacimab once a month for about three months.
  • It’s for people already using another preventative HAE treatment.
  • Understanding treatment switches helps doctors improve HAE care.

من قد يكون مؤهلاً؟

To join this study, you must be at least 12 years old. You need to have a clear diagnosis of hereditary angioedema (HAE), type 1 or type 2. This diagnosis should be confirmed by your doctor's records, including showing you have the right symptoms and specific blood test results that indicate HAE. Your medical history should also show that on-demand treatments (medicines taken during an attack) have worked for you in the past.

You should currently be taking a regular preventative medicine for your HAE, such as lanadelumab, berotralstat, or a plasma-derived C1-esterase inhibitor. You must have been on a steady dose of this medicine for at least three months before the study starts. This helps researchers see how the switch to garadacimab affects you, rather than changes in your old medicine.

There are also reasons why you might not be able to join. For example, if you have another type of angioedema alongside HAE, or if you're taking certain other medicines (like androgens or antifibrinolytics) to prevent HAE attacks. You also can't join if you're allergic to garadacimab.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك 12 سنة أو أكثر؟
  2. Do you have a confirmed diagnosis of hereditary angioedema (HAE)?
  3. Are you currently taking a regular preventative medicine for your HAE?
  4. Have you been on a stable dose of this medicine for at least three months?
  5. Have your on-demand HAE treatments worked for you in the past?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, you will first go through a screening process to make sure you are suitable. Once confirmed, you will switch from your current HAE preventative medicine to the study medicine, garadacimab. You will receive garadacimab once a month for about three months. This will involve regular visits to the clinic where you will have health checks, blood tests, and doctors will ask about your HAE attacks and any side effects you might experience. The total duration of your participation in the study, from your initial checks to your final follow-up, will be clearly explained to you by the study team.

المخاطر والفوائد المحتملة

Participating in this study might offer potential benefits, such as trying a new preventative treatment for your HAE, which could potentially work well for you. However, as with any medicine, there are also potential risks, including side effects from garadacimab or feeling unwell as you switch from your current medication. All known risks will be clearly explained to you by the study team. Remember, taking part is completely voluntary, and you are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

المواقع (11)

  • Research Solutions of Arizona
    الرمز البريدي المؤكد
    Litchfield Park, United States
  • Allergy and Asthma Clinic of Northwest Arkansas
    الرمز البريدي المؤكد
    Bentonville, United States
  • Donald Levy M.D.
    الرمز البريدي المؤكد
    أورانج، الولايات المتحدة
  • Raffi Tachdjian MD, Inc.
    الرمز البريدي المؤكد
    سانتا مونيكا، الولايات المتحدة
  • Bernstein Clinical Research Center, LLC
    الرمز البريدي المؤكد
    سينسيناتي، الولايات المتحدة
  • Chronicle Bio
    الرمز البريدي المؤكد
    مدينة وادي الغرب، الولايات المتحدة
  • McMaster University-Hamilton
    الرمز البريدي المؤكد
    هاميلتون، كندا
  • Montreal Clinical Research Institute
    الرمز البريدي المؤكد
    مونتريال، كندا
  • Clinique Spécialisée en Allergie de la Capitale
    الرمز البريدي المؤكد
    كيبك، كندا
  • HZRM Hämophilie Zentrum Rhein Main GmbH
    الرمز البريدي المؤكد
    فرانكفورت، ألمانيا
  • Hautklinik und Poliklinik der Universitätsklinik Mainz
    الرمز البريدي المؤكد
    ماينز، ألمانيا

أسئلة شائعة

ما هو الوذمة الوعائية الوراثية (HAE)؟

HAE is a rare genetic condition that causes sudden and unpredictable swelling attacks, often in the face, hands, feet, tummy, or throat.

What is garadacimab?

Garadacimab is a medicine being studied to help prevent HAE attacks.

لماذا يحدث هذا البحث؟

This study aims to find out how safe it is for people with HAE to switch from their current preventative medicine to garadacimab.

من يمكنه الانضمام إلى هذه الدراسة؟

People aged 12 and over with HAE who are currently taking another regular medicine to prevent their HAE attacks could be eligible.

كم ستستغرق الدراسة بالنسبة لي؟

If you join, you would take garadacimab once a month for about three months as part of the study.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.